AstraZeneca CEO Pascal Soriot said it’s time for the U.S. to start paying more reasonable prices for new drugs, which are closer to what other wealthy countries pay, in a rare stance in an industry ...

AstraZeneca's CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 billion in manufacturing.

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

AstraZeneca said it is investing $50 billion in US manufacturing by 2030, following the lead of big pharma peers that have ...

The U.K.-based drugmaker plans to invest $50 billion in the United States as the industry seeks to appease President Trump.

With the threat of tariffs looming for medicines imported to the United States, AstraZeneca has unveiled a plan to invest $50 ...

British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States by 2030 amid US leader ...